Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Soluble fusion protein used for treatment of Rheumatoid Arthritis and other autoimmune diseases.
Abatacept is a biological disease-modifying antirheumatic drug (DMARD).
Weekly administration subcutaneously.
Its very high molecular weight probably explain the negligible excretion observed in milk (Saito 2019). No health or immunization problems have been observed in an infant breastfed by a mother treated with abatacept (Saito 2019).
Its nil oral bioavailability would make it difficult its passage to the infant’s plasma through breast milk except in premature babies and in the immediate neonatal period during which there may be greater intestinal permeability.
Several medical societies, experts and expert consensus, consider the use of this medication to be compatible or very probably compatible during breastfeeding if no other options are available (Sammaritano 2020, Hale 2019, Götestam 2016).